Fluorescent Kinetic Profiling Assay for High-Throughput Drug Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the kinetic profile of compounds in drug discovery are time-consuming, costly, and limited in throughput, often requiring radiolabeling and sophisticated equipment, which restricts the analysis to later stages of drug development and fails to provide comprehensive kinetic data for high-throughput screening.
Innovation Solution
A method that calculates the kinetic profile of compounds against target proteins or polyproteins using a competitive binding assay with fluorescent probes, allowing simultaneous measurement of affinity, association, and dissociation rates without pre-determining the inhibitor constant, enabling high-throughput screening and reducing the need for radiolabeling and complex equipment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radioligand binding competition assays are used to determine kinetic profiles, then measurement precision is improved, but productivity deteriorates due to tedious and time-consuming procedures
Solution Approach 1:
The patent replaces the mechanical filtration and washing steps of radioligand assays with a homogeneous fluorescent-based detection system. The method uses fluorescently labeled ligands that allow direct measurement of binding kinetics without requiring physical separation of bound and free ligand, thereby eliminating tedious filtration steps while maintaining measurement precision.
Solution Approach 2:
The patent introduces fluorescently labeled ligands as intermediaries to mediate the detection of binding events. These fluorescent ligands serve as reporters that enable real-time monitoring of kinetic parameters through fluorescence intensity changes, replacing the need for radiolabeling and complex separation procedures while improving throughput.
2Ease of operation
If sophisticated liquid handling systems with cherry-picking are used to automate kinetic assays, then ease of operation is improved, but device complexity increases
Solution Approach 1:
The patent segments the kinetic assay into simple, discrete steps that can be performed in standard microplate formats. By dividing the assay into separate wells for different time points and using straightforward addition of reagents, the method enables automation with basic liquid handling equipment rather than requiring complex cherry-picking systems.
Solution Approach 2:
The patent uses identical assay conditions and reagent compositions across multiple wells and replicates, allowing standard liquid handling systems to simply dispense the same mixture into multiple locations. This eliminates the need for sophisticated systems that must handle varying volumes and compositions, as the assay design allows uniform treatment of all samples.
3Measurement precision
If pre-incubation at high ligand concentrations is performed to occupy binding sites, then measurement precision is improved, but loss of time increases due to multiple incubation steps
Solution Approach 1:
The patent performs preliminary characterization of the fluorescent ligand's binding properties (Kd, kon, koff) in separate validation experiments. Once these parameters are established, the main kinetic assays can proceed with simplified protocols that do not require time-consuming pre-incubation steps, as the binding behavior is already known and can be accurately modeled.
Solution Approach 2:
The patent changes the detection parameter from measuring bound vs. free ligand separation to measuring fluorescence intensity changes directly. This parameter change allows the use of lower ligand concentrations and shorter incubation times, as the fluorescent signal provides real-time information about binding events without requiring complete site occupancy or multiple washing steps.
4Measurement precision
If extensive washing steps are performed to separate bound from free radioligand, then measurement precision is improved, but loss of substance increases due to material loss during filtration
Solution Approach 1:
The patent replaces the mechanical filtration and washing system with a homogeneous fluorescent detection system. By using fluorescently labeled ligands and measuring fluorescence intensity directly in the solution phase, the method eliminates the need for physical separation steps that cause material loss, thereby maintaining measurement precision without sacrificing ligand.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method simplifies the determination of kinetic profiles, reducing time and costs, and enables the analysis of multiple compounds in early drug discovery stages, providing comprehensive kinetic data for improved drug candidate selection and safety assessment.
Implementation Method 1
a first molecule having affinity for said target protein or polyprotein and labeled with a first fluorescent molecule
Implementation Method 2
wherein said first fluorescent molecule is an acceptor fluorophore and said second fluorescent molecule is a donor fluorophore
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a reliable, robust and sensitive platform aimed to analyze the massive kinetic profile of new molecules against its main target and also against other potential targets. Thus, the present invention relates to a method for calculating the kinetic profile of a compound of interest against a target protein or polyprotein wherein it is not needed to predetermine the K, value of the compound of interest against the target protein or polyprotein before starting the assay. The present invention also discloses the use of said method in a high-throughput system for developing a Binding Kinetic Profiling assay of multiple compounds of interest against a unique target, or a Kinetic Selectivity Profiling assay of one selected compound against multiple target proteins or polyproteins to therefore establish multiple clinical profiles of potential drugs.